News
PAHC
12.05
+0.58%
0.07
Phibro Animal Health First Quarter 2023 Earnings: EPS Misses Expectations
Phibro Animal Health ( NASDAQ:PAHC ) First Quarter 2023 Results Key Financial Results Revenue: US$232.5m (up 8.3% from...
Simply Wall St. · 11/11 10:27
Morgan Stanley Maintains Equal-Weight on Phibro Animal Health, Lowers Price Target to $20
Benzinga · 11/10 13:36
--Morgan Stanley Adjusts Price Target on Phibro Animal Health to $20 From $21, Maintains Equalweight Rating
--Morgan Stanley Adjusts Price Target on Phibro Animal Health to $20 From $21, Maintains Equalweight Rating
MT Newswires · 11/10 09:33
Phibro Animal Non-GAAP EPS of $0.21 misses by $0.06, revenue of $232.5M beats by $0.41M
Seekingalpha · 11/09 21:57
Phibro Animal Health Q1 EPS $0.21 Misses $0.26 Estimate, Sales $232.50M Beat $227.54M Estimate
Benzinga · 11/09 21:38
BRIEF-Phibro Animal Health Corporation Reports First Quarter Results
Reuters · 11/09 21:27
-- Earnings Flash (PAHC) PHIBRO ANIMAL HEALTH CORPORATION Posts Q1 EPS $0.21
-- Earnings Flash (PAHC) PHIBRO ANIMAL HEALTH CORPORATION Posts Q1 EPS $0.21
MT Newswires · 11/09 16:41
-- Earnings Flash (PAHC) PHIBRO ANIMAL HEALTH CORPORATION Reports Q1 Revenue $232.5M
-- Earnings Flash (PAHC) PHIBRO ANIMAL HEALTH CORPORATION Reports Q1 Revenue $232.5M
MT Newswires · 11/09 16:34
Phibro Animal Health Corporation (NASDAQ:PAHC) Has A ROE Of 19%
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
Simply Wall St. · 11/09 14:52
Phibro Animal declares $0.12 dividend
Seekingalpha · 11/07 21:31
AdaptHealth Corp. (AHCO) Stock Jumps 5.2%: Will It Continue to Soar?
AdaptHealth Corp. (AHCO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks · 09/19 12:54
Barclays Maintains Underweight on Phibro Animal Health, Lowers Price Target to $17
Barclays analyst Balaji Prasad maintains Phibro Animal Health (NASDAQ:PAHC) with a Underweight and lowers the price target from $22 to $17.
Benzinga · 09/16 10:38
--Barclays Adjusts Price Target on Phibro Animal Health to $17 From $22, Reiterates Underweight Rating
--Barclays Adjusts Price Target on Phibro Animal Health to $17 From $22, Reiterates Underweight Rating
MT Newswires · 09/16 07:04
Phirbo (PAHC) Faces Rising Costs and Inflationary Pressure
Price competition coming from cheap generic alternatives of a few Phirbo (PAHC) products is a deterrent.
Zacks · 09/15 16:34
Phibro Animal Health's Return On Capital Employed Insights
Pulled from Benzinga Pro data, Phibro Animal Health (NASDAQ:PAHC) showed a loss in earnings since Q3, totaling $7.49 million. Sales, on the other hand, increased by 6.55% to $255.30 million during Q4.
Benzinga · 09/13 14:02
Investors five-year losses continue as Phibro Animal Health (NASDAQ:PAHC) dips a further 8.3% this week, earnings continue to decline
Generally speaking long term investing is the way to go. But no-one is immune from buying too high. For example the...
Simply Wall St. · 09/05 17:33
Morgan Stanley Maintains Equal-Weight on Phibro Animal Health, Lowers Price Target to $21
Morgan Stanley analyst Erin Wright maintains Phibro Animal Health (NASDAQ:PAHC) with a Equal-Weight and lowers the price target from $23 to $21.
Benzinga · 08/26 12:29
--Morgan Stanley Trims Price Target on Phibro Animal Health to $21 From $23, Keeps Equalweight Rating
--Morgan Stanley Trims Price Target on Phibro Animal Health to $21 From $23, Keeps Equalweight Rating
MT Newswires · 08/26 07:36
Phibro Animal Clocks 16% Jump In Q4 Sales, Plans Incremental Strategic Investments In Future
Benzinga · 08/25 13:38
More
Webull provides a variety of real-time PAHC stock news. You can receive the latest news about Phibro Animal through multiple platforms. This information may help you make smarter investment decisions.
About PAHC
Phibro Animal Health Corporation is a diversified animal health and mineral nutrition company. The Company develops and markets a range of products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The Company operates through three segments, which include Animal Health, Mineral Nutrition and Performance Products. Its Animal health segment includes products, such as antibacterial, anticoccidials, nutritional specialty products and vaccines. This segment also includes antibacterial and other processing aids used in the ethanol fermentation industry. Its Mineral Nutrition segment manufactures and markets approximately 400 formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron and other compounds. Its Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries, primarily in the United States.